Launch of DermaSys Brand

Futura Medical PLC 28 February 2007 For immediate release 28 February 2007 Futura Medical Plc Launches DermaSys(R) as brand name for proprietary drug delivery technology Futura Medical plc (Futura), the AIM-listed pharmaceutical group that develops innovative products for the consumer healthcare market, announces the launch of DermaSys(R) as the brand name for its versatile gel technology for the rapid delivery of drugs through the skin. The DermaSys(R) technology was originally developed by Futura for use in the Company's topical treatment for erectile dysfunction, MED2002. Futura is continuing its assessment program for DermaSys(R) against a wide range of generic drugs suited to topical delivery where substantial improvements in speed of absorption and permeability across the skin would result in attractive commercial opportunities. For more information please visit the Futura website by clicking on the following link: http://www.futuramedical.co.uk/content/ products/delivery_technology.asp DermaSys(R) is a versatile and bespoke technology which can be adapted to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects. James Barder, Futura Medical's Chief Executive, said: 'We are pleased to announce the launch of DermaSys(R) as the brand name of our proprietary drug delivery technology. DermaSys(R) is an important asset within Futura and we intend to continue to exploit its potential.' For further information: Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 685 670 mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Media enquiries: Buchanan Communications Mark Court / Rebecca Dietrich Tel: +44 (0) 020 7466 5000 Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products for the consumer healthcare market with a strong expertise in sexual health. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura's primary focus is on over-the-counter products with particular appeal to men and women who are reluctant to discuss potentially embarrassing sexual matters with their doctors. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange
UK 100